Ποια είναι η τιμή για 9 Meters Biopharma, Inc. (NMTR)

Η τιμή για 9 Meters Biopharma, Inc. (NMTR) είναι $0.0169

Ποια είναι η κεφαλαιοποίηση αγοράς για 9 Meters Biopharma, Inc. (NMTR)

Η κεφαλαιοποίηση αγοράς για 9 Meters Biopharma, Inc. (NMTR) είναι $66.40K

9 Meters Biopharma, Inc. (NMTR) Τιμή και Κεφαλαιοποίηση Αγοράς

Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. Its core mission is to innovate treatments for individuals suffering from rare digestive conditions, gastrointestinal disorders with inadequate therapeutic options, and other severe debilitating ailments. The company's pipeline features several promising drug candidates. Larazotide, an 8-amino acid peptide, is currently in a Phase 3 clinical trial for the treatment of celiac disease and is also being assessed in a Phase IIa study for multi-system inflammatory syndrome. Another key asset, Vurolenatide, a long-acting injectable glucagon-like peptide-1, is undergoing Phase 2 clinical trials to address short bowel syndrome. Additionally, 9 Meters Biopharma is advancing other compounds, including NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody designed to target specific obesity disorders; and NM-004, a double-cleaved mesalamine combined with an immunomodulator, slated for rare and/or orphan indications.

Η τιμή για NMTR	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$1,392,094 $66.40K	NVDA	$5.470T	+8,237,243,184.27%
$1,136,949 $66.40K	AAPL	$4.467T	+6,727,506,640.60%
$1,062,455 $66.40K	GOOG	$4.174T	+6,286,716,887.50%
$941,735 $66.40K	MSFT	$3.700T	+5,572,397,094.43%
$726,481 $66.40K	AMZN	$2.854T	+4,298,702,310.84%

Η τιμή για NMTR

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$1,392,094 $66.40K